Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 17-valerate, Betamethasone
2. Betamethasone 17 Valerate
3. Betamethasone 17-valerate
4. Betnovate
5. Flubenisolonvalerate
6. Valerate, Betamethasone
1. Betamethasone 17-valerate
2. 2152-44-5
3. Betnovate
4. Betaderm
5. Luxiq
6. Beta-val
7. Betatrex
8. Tokuderm
9. Valnac
10. Betamethasone-17-valerate
11. Celestoderm
12. Bedermin
13. Bextasol
14. Stanoval
15. Rinderon V
16. Dermovaleas
17. Betneval
18. Dermosol
19. Beta-methasone 17-valerate
20. Ecoval 70
21. Betamethasone 17a-valerate
22. Betamethasone (as Valerate)
23. 9ifa5xm7r2
24. Chebi:31277
25. Betamethasone Valerate (betnovate)
26. Nsc-755912
27. [(8s,9r,10s,11s,13s,14s,16s,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Pentanoate
28. Betnovateat
29. Celeston Valerate
30. 9-fluoro-11.beta.,17,21-trihydroxy-16.beta.-methylpregna-1,4-diene-3,20-dione 17-valerate
31. 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione-17-valerate
32. 9-fluoro-11beta,21-dihydroxy-16beta-methyl-3,20-dioxopregna-1,4-dien-17-yl Pentanoate
33. 9-fluoro-11beta,21-dihydroxy-16beta-methyl-3,20-dioxopregna-1,4-dien-17-yl Valerate
34. Topagen (veterinary)
35. Gentocin (veterinary)
36. Betamethasone Valerate (betamethasone 17-valerate)
37. Bettamousse
38. Betaval
39. Fuciderm
40. Betoid
41. Celestoderm V
42. Celestoderm-v
43. Betnesol V
44. Betnesol-v
45. Celestan V
46. Celestan-v
47. Celestane V
48. Ncgc00274064-01
49. Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-((1-oxopentyl)oxy)-, (11.beta.,16.beta.)-
50. Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-[(1-oxopentyl)oxy]-, (11.beta.,16.beta.)-
51. Einecs 218-439-3
52. Betamethasoni Valeras
53. Rinderon-v (tn)
54. Betamethasone-valerate
55. Luxiq (tn)
56. Topagen (salt/mix)
57. Beta-val (tn)
58. Betatrex (salt/mix)
59. Gentocin (salt/mix)
60. Chlorophytum Borivilanum
61. Betamethason-17-valerate
62. Dsstox_cid_2673
63. Unii-9ifa5xm7r2
64. Schembl7270
65. Chembl1497
66. Dsstox_rid_76684
67. Dsstox_gsid_22673
68. Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-((1-oxopentyl)oxy)-, (11beta,16beta)-
69. Betamethasone 17alpha-valerate
70. Dtxsid7022673
71. Hy-b0727
72. Zinc3882052
73. Betamethasone Valerate (jp17/usp)
74. Betamethasone Valerate [jan]
75. Tox21_302288
76. Betamethasone Valerate [usan]
77. S1690
78. Betamethasone Valerate [vandf]
79. Akos015994704
80. Betamethasone Valerate [mart.]
81. Betamethasone Valerate [usp-rs]
82. Betamethasone Valerate [who-dd]
83. Betamethasone Valerate [who-ip]
84. Ccg-269509
85. Ks-1198
86. Nsc 755912
87. 9-fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione-17-valerate
88. 9-fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-valerate
89. Betamethasone 17-valerate [mi]
90. Betamethasone Valerate [usan:usp:jan]
91. Ncgc00255185-01
92. (11beta,16beta)-9-fluoro-11,21-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl Pentanoate
93. (2s,10s,11s,13s,15s,17s,1r,14r)-1-fluoro-17-hydroxy-14-(2-hydroxyacetyl)-2,13, 15-trimethyl-5-oxotetracyclo[8.7.0.0<2,7>.0<11,15>]heptadeca-3,6-dien-14-yl Pe Ntanoate
94. Betamethasone Valerate [green Book]
95. Cas-2152-44-5
96. Betamethasone Valerate [orange Book]
97. Betamethasone Valerate [ep Monograph]
98. Betamethasone Valerate For System Suitability
99. Betamethasoni Valeras [who-ip Latin]
100. Cs-0009628
101. Betamethasone Valerate [usp Monograph]
102. D01357
103. Ab01274710-01
104. Ab01274710_02
105. 152m445
106. A815447
107. Q6445931
108. Betamethasone 17a-valerate 100 Microg/ml In Methanol
109. Brd-k34032314-001-04-1
110. (11.beta.,16.beta.)-9.alpha.-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione 17.alpha.-valerate
111. (8s,9r,10s,11s,13s,14s,16s,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl Pentanoate
112. 9-fluoro-11.beta.,21-dihydroxy-16.beta.-methyl-3,20-dioxopregna-1,4-dien-17-yl Pentanoate #
| Molecular Weight | 476.6 g/mol |
|---|---|
| Molecular Formula | C27H37FO6 |
| XLogP3 | 3.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 7 |
| Exact Mass | 476.25741706 g/mol |
| Monoisotopic Mass | 476.25741706 g/mol |
| Topological Polar Surface Area | 101 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 957 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Betamethasone valerate |
| PubMed Health | Betamethasone Valerate (On the skin) |
| Drug Classes | Corticosteroid, Intermediate |
| Drug Label | Luxq Foam contains betamethasone valerate, USP, a synthetic corticosteroid, for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory agents.Betamethasone valerate is 9-... |
| Active Ingredient | Betamethasone valerate |
| Dosage Form | Lotion; Ointment; Cream; Aerosol, foam |
| Route | Topical |
| Strength | 0.12%; eq 0.1% base |
| Market Status | Prescription |
| Company | Sti Pharma; Actavis Mid Atlantic; Perrigo; Fougera |
| 2 of 2 | |
|---|---|
| Drug Name | Betamethasone valerate |
| PubMed Health | Betamethasone Valerate (On the skin) |
| Drug Classes | Corticosteroid, Intermediate |
| Drug Label | Luxq Foam contains betamethasone valerate, USP, a synthetic corticosteroid, for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory agents.Betamethasone valerate is 9-... |
| Active Ingredient | Betamethasone valerate |
| Dosage Form | Lotion; Ointment; Cream; Aerosol, foam |
| Route | Topical |
| Strength | 0.12%; eq 0.1% base |
| Market Status | Prescription |
| Company | Sti Pharma; Actavis Mid Atlantic; Perrigo; Fougera |
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - CREAM;TOPICAL - EQ 0.1% BASE
USFDA APPLICATION NUMBER - 18861
DOSAGE - OINTMENT;TOPICAL - EQ 0.1% BASE
USFDA APPLICATION NUMBER - 18865
DOSAGE - LOTION;TOPICAL - EQ 0.1% BASE
USFDA APPLICATION NUMBER - 18866
DOSAGE - AEROSOL, FOAM;TOPICAL - 0.12%
USFDA APPLICATION NUMBER - 20934
Related Excipient Companies
Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Solubilizers
Thickeners and Stabilizers
Emulsifying Agents
Controlled & Modified Release
Film Formers & Plasticizers
Surfactant & Foaming Agents
Granulation
Lubricants & Glidants
Rheology Modifiers
Coating Systems & Additives
Parenteral
Direct Compression
Digital Content
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
55
PharmaCompass offers a list of Betamethasone Valerate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Betamethasone Valerate manufacturer or Betamethasone Valerate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Betamethasone Valerate manufacturer or Betamethasone Valerate supplier.
PharmaCompass also assists you with knowing the Betamethasone Valerate API Price utilized in the formulation of products. Betamethasone Valerate API Price is not always fixed or binding as the Betamethasone Valerate Price is obtained through a variety of data sources. The Betamethasone Valerate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Betamethason-17-valerate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Betamethason-17-valerate, including repackagers and relabelers. The FDA regulates Betamethason-17-valerate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Betamethason-17-valerate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Betamethason-17-valerate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Betamethason-17-valerate supplier is an individual or a company that provides Betamethason-17-valerate active pharmaceutical ingredient (API) or Betamethason-17-valerate finished formulations upon request. The Betamethason-17-valerate suppliers may include Betamethason-17-valerate API manufacturers, exporters, distributors and traders.
click here to find a list of Betamethason-17-valerate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Betamethason-17-valerate DMF (Drug Master File) is a document detailing the whole manufacturing process of Betamethason-17-valerate active pharmaceutical ingredient (API) in detail. Different forms of Betamethason-17-valerate DMFs exist exist since differing nations have different regulations, such as Betamethason-17-valerate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Betamethason-17-valerate DMF submitted to regulatory agencies in the US is known as a USDMF. Betamethason-17-valerate USDMF includes data on Betamethason-17-valerate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Betamethason-17-valerate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Betamethason-17-valerate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Betamethason-17-valerate Drug Master File in Japan (Betamethason-17-valerate JDMF) empowers Betamethason-17-valerate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Betamethason-17-valerate JDMF during the approval evaluation for pharmaceutical products. At the time of Betamethason-17-valerate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Betamethason-17-valerate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Betamethason-17-valerate Drug Master File in Korea (Betamethason-17-valerate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Betamethason-17-valerate. The MFDS reviews the Betamethason-17-valerate KDMF as part of the drug registration process and uses the information provided in the Betamethason-17-valerate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Betamethason-17-valerate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Betamethason-17-valerate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Betamethason-17-valerate suppliers with KDMF on PharmaCompass.
A Betamethason-17-valerate CEP of the European Pharmacopoeia monograph is often referred to as a Betamethason-17-valerate Certificate of Suitability (COS). The purpose of a Betamethason-17-valerate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Betamethason-17-valerate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Betamethason-17-valerate to their clients by showing that a Betamethason-17-valerate CEP has been issued for it. The manufacturer submits a Betamethason-17-valerate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Betamethason-17-valerate CEP holder for the record. Additionally, the data presented in the Betamethason-17-valerate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Betamethason-17-valerate DMF.
A Betamethason-17-valerate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Betamethason-17-valerate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Betamethason-17-valerate suppliers with CEP (COS) on PharmaCompass.
A Betamethason-17-valerate written confirmation (Betamethason-17-valerate WC) is an official document issued by a regulatory agency to a Betamethason-17-valerate manufacturer, verifying that the manufacturing facility of a Betamethason-17-valerate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Betamethason-17-valerate APIs or Betamethason-17-valerate finished pharmaceutical products to another nation, regulatory agencies frequently require a Betamethason-17-valerate WC (written confirmation) as part of the regulatory process.
click here to find a list of Betamethason-17-valerate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Betamethason-17-valerate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Betamethason-17-valerate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Betamethason-17-valerate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Betamethason-17-valerate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Betamethason-17-valerate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Betamethason-17-valerate suppliers with NDC on PharmaCompass.
Betamethason-17-valerate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Betamethason-17-valerate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Betamethason-17-valerate GMP manufacturer or Betamethason-17-valerate GMP API supplier for your needs.
A Betamethason-17-valerate CoA (Certificate of Analysis) is a formal document that attests to Betamethason-17-valerate's compliance with Betamethason-17-valerate specifications and serves as a tool for batch-level quality control.
Betamethason-17-valerate CoA mostly includes findings from lab analyses of a specific batch. For each Betamethason-17-valerate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Betamethason-17-valerate may be tested according to a variety of international standards, such as European Pharmacopoeia (Betamethason-17-valerate EP), Betamethason-17-valerate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Betamethason-17-valerate USP).
